Biotechnology in Health Solutions
- Select a blog category
by Dr. Mark Steedman, Research Manager, Centre for Health Solutions
Our recent report The future awakens: Life sciences and health care predictions 2022, uses evidence from today to predict what the world will look like in the year 2022. One of our predictions, ‘The future of medicine is here and now,’ explores how exponential advances in life-extending and precision therapies will improve patient outcomes. Much of the evidence informing this prediction is derived from advances in areas such as genomics, precision medicine and new cancer treatments, including CAR-T cell therapies. However, advances in other scientific areas, such as tissue engineering, are also gaining traction. This week’s blog explores developments in tissue engineering as a whole and zeros in on an exciting new development in retinal tissue engineering.
In December 2015 we launched our sixth annual report on ‘Measuring the return from pharmaceutical innovation’. Our research highlights the difficulties that the largest pharmaceutical companies face in delivering sustainable returns on their late stage R&D pipelines. Indeed, while the cost to develop an asset has increased by a third since we started our analysis six years ago, forecast average peak sales has declined by half. Additionally, our measure of forecast R&D return on investment (RoI) has also shown a significant downward trend, with the average across the 12 companies declining from over ten per cent in 2010 to just over four per cent in 2015.
You may have seen the headlines this week that pharma R&D returns are at their lowest level for at least 5 years. This comes from our 6th ‘Measuring the returns from pharmaceutical R&D’ report – an annual study which I have worked on for the last three years. I thought I’d take this opportunity to reflect on the origins of this report and its contribution to the debate on pharma R&D productivity.
On 29 September a report on the Genomics industry in the UK which we had prepared for the Office for Life Sciences was published. The report looks at the size, growth trends and industry composition of the market and provides insight into the potential drivers, challenges and opportunities facing the industry in the UK.i This blog highlights some of the key trends in human genomics, the development of the emergent UK market and the barriers that will need to be overcome if the benefits to the UK are to be fully realised.
This week the Center for Health Solutions is delighted to bring you a guest blog from one of our consultants in health care and life sciences:
The life science industry is facing significant challenges such as patent cliffs, pricing and market access restrictions as well as increasing regulatory pressure. These challenges fundamentally call into question traditional business models and, as a result, life science companies are increasingly looking to new and innovative ways to tackle these challenges
This week the Center for Health Solutions is delighted to bring you a guest blog from one of our regulatory compliance specialists in health care and life sciences: